Injenta Duo Tablet 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
MFDS item code 202001549 · Approved 2020.03.05
This product's status changed to Expired on 2025.03.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to help control blood sugar levels in adults with type 2 diabetes. It is used in individuals who have not yet received other diabetes medication treatment or in those who have difficulty controlling blood sugar levels with monotherapy. This medication may be administered when sufficient effects are not achieved with monotherapy using metformin or combination therapy with linagliptin and metformin. Additionally, it can be used in conjunction with metformin and sulfonylurea therapy or insulin and metformin therapy when blood sugar control is difficult. This medication can also be used when combination therapy with empagliflozin and metformin is insufficient. It aids in improving blood sugar control as an adjunctive therapy in various combination therapies.
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medication should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with caution to the following patients). 5. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used for the treatment of diabetes and one of its active ingredients, metformin hydrochloride, may cause a serious side effect known as lactic acidosis; hence, caution is required. This medication should not be administered to certain patients. For example, individuals with allergies to this medication, patients with type 1 diabetes, those with severe renal impairment, patients with acute heart disease or severe infections, individuals with liver function impairment, and pregnant or breastfeeding women should not use this medication. Also, this medication carries a risk of hypoglycemia; thus, blood sugar fluctuations should be closely monitored when used in conjunction with insulin or sulfonylureas, and dosage adjustments may be necessary. Lactic acidosis, although rare, can be a fatal side effect. The risk increases if renal function deteriorates rapidly or if there are severe infections, dehydration, or excessive alcohol consumption. Therefore, in such cases, this medication should be temporarily discontinued, and the patient should consult a doctor immediately. During the use of this medication, regular monitoring of kidney function is necessary, especially for elderly patients or those with reduced kidney function. Patients with poor heart function should also use this medication cautiously and must discontinue it before and after the administration of iodinated contrast agents used in radiologic tests. Acute pancreatitis or skin conditions such as bullous pemphigoid may occur, so if these symptoms arise, the patient should notify a doctor immediately and discontinue the medication. This medication may decrease vitamin B12 levels; therefore, it is advisable to regularly check for vitamin B12 deficiency if used over a long period. Moreover, this medication may interact with various other medications. If the patient is taking other drugs, a consultation with a doctor or pharmacist is recommended, especially when combined with medications affecting kidney function. Pregnant or breastfeeding women are advised not to use this medication, and it is not recommended for children or adolescents. Elderly patients may need dosage adjustments due to declining kidney function and should have regular kidney function tests. In cases of overdose, there is a risk of lactic acidosis, and immediate medical attention is necessary, which may also require hemodialysis. Lastly, this medication should be kept out of reach of children, stored away from moisture, and not transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. The storage temperature should be maintained at room temperature between 1 degree and 30 degrees Celsius. This will help preserve the medication's efficacy for a longer duration.
Bright pink, biconvex, oval-shaped film-coated tablet
60 tablets/box [10 tablets/PTP x 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.